Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

Shinya Goto; Hisao Ogawa; Masaru Takeuchi; Marcus D Flather; Deepak L Bhatt; J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators

doi:10.1093/eurheartj/ehq320

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

Shinya Goto
, Hisao Ogawa
, Masaru Takeuchi
, Marcus D Flather
, Deepak L Bhatt
, J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators

Research output: Contribution to journal › Article › peer-review

150 Citations (Scopus)

Abstract

Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).

Original language	English
Pages (from-to)	2601-13
Number of pages	13
Journal	European Heart Journal
Volume	31
Issue number	21
DOIs	https://doi.org/10.1093/eurheartj/ehq320
Publication status	Published - Nov 2010

Keywords

Acute Coronary Syndrome
Administration, Oral
Coronary Artery Disease
Double-Blind Method
Drug-Induced Liver Injury
Female
Hemorrhage
Humans
Imines
Long QT Syndrome
Male
Middle Aged
Platelet Aggregation Inhibitors
Pyridines
Receptor, PAR-1

Access to Document

10.1093/eurheartj/ehq320

Cite this

Goto, S., Ogawa, H., Takeuchi, M., Flather, M. D., Bhatt, D. L., & J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators (2010). Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal, 31(21), 2601-13. https://doi.org/10.1093/eurheartj/ehq320

@article{2435280e997746fea916e472ab53317f,

title = "Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease",

abstract = "Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).",

keywords = "Acute Coronary Syndrome, Administration, Oral, Coronary Artery Disease, Double-Blind Method, Drug-Induced Liver Injury, Female, Hemorrhage, Humans, Imines, Long QT Syndrome, Male, Middle Aged, Platelet Aggregation Inhibitors, Pyridines, Receptor, PAR-1",

author = "Shinya Goto and Hisao Ogawa and Masaru Takeuchi and Flather, \{Marcus D\} and Bhatt, \{Deepak L\} and \{J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators\}",

year = "2010",

month = nov,

doi = "10.1093/eurheartj/ehq320",

language = "English",

volume = "31",

pages = "2601--13",

journal = "European Heart Journal",

issn = "0195-668X",

publisher = "Oxford University Press",

number = "21",

}

Goto, S, Ogawa, H, Takeuchi, M, Flather, MD, Bhatt, DL & J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators 2010, 'Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease', European Heart Journal, vol. 31, no. 21, pp. 2601-13. https://doi.org/10.1093/eurheartj/ehq320

Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. / Goto, Shinya; Ogawa, Hisao; Takeuchi, Masaru et al.
In: European Heart Journal, Vol. 31, No. 21, 11.2010, p. 2601-13.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease

AU - Goto, Shinya

AU - Ogawa, Hisao

AU - Takeuchi, Masaru

AU - Flather, Marcus D

AU - Bhatt, Deepak L

AU - J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators

PY - 2010/11

Y1 - 2010/11

N2 - Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).

AB - Two multicentre, randomized, double-blind, placebo-controlled Phase II studies assessed the safety and efficacy of the oral protease-activated receptor 1 (PAR-1) antagonist E5555 in addition to standard therapy in Japanese patients with acute coronary syndrome (ACS) or high-risk coronary artery disease (CAD).

KW - Acute Coronary Syndrome

KW - Administration, Oral

KW - Coronary Artery Disease

KW - Double-Blind Method

KW - Drug-Induced Liver Injury

KW - Female

KW - Hemorrhage

KW - Humans

KW - Imines

KW - Long QT Syndrome

KW - Male

KW - Middle Aged

KW - Platelet Aggregation Inhibitors

KW - Pyridines

KW - Receptor, PAR-1

U2 - 10.1093/eurheartj/ehq320

DO - 10.1093/eurheartj/ehq320

M3 - Article

C2 - 20805115

SN - 0195-668X

VL - 31

SP - 2601

EP - 2613

JO - European Heart Journal

JF - European Heart Journal

IS - 21

ER -

Goto S, Ogawa H, Takeuchi M, Flather MD, Bhatt DL, J-LANCELOT (Japanese-Lesson from Antagonizing the Cellular Effect of Thrombin) Investigators. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. European Heart Journal. 2010 Nov;31(21):2601-13. doi: 10.1093/eurheartj/ehq320